Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;106:1410-1419
Published online before print August 19, 2002, doi: 10.1161/01.CIR.0000028587.85711.F6
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/11/1410    most recent
01.CIR.0000028587.85711.F6v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyata, A.
Right arrow Articles by Rubart, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyata, A.
Right arrow Articles by Rubart, M.
Related Collections
Right arrow Arrythmias-basic studies

(Circulation. 2002;106:1410.)
© 2002 American Heart Association, Inc.


Basic Science Reports

KB-R7943 Prevents Acute, Atrial Fibrillation–Induced Shortening of Atrial Refractoriness in Anesthetized Dogs

Akira Miyata, MD; Douglas P. Zipes, MD; Stephen Hall, PhD; Michael Rubart, MD

From the Krannert Institute of Cardiology (A.M., D.P.Z., M.R.) and Department of Medicine, Division of Clinical Pharmacology (S.H.), Wishard Memorial Hospital, Indianapolis, Ind.

Correspondence to Michael Rubart, MD, Wells Center for Pediatric Research, Riley Hospital, 702 Barnhill Dr, Indianapolis, IN 46202. E-mail mrubartv{at}iupui.edu

Background— To test the hypothesis that Ca2+ influx via Na+/Ca2+ exchange (NCX) underlies atrial fibrillation (AF)–induced shortening of atrial effective refractory period (AERP), we examined the potential of KB-R7943 (KB), a selective inhibitor of Ca2+-influx mode NCX, to attenuate this effect.

Methods and Results— Studies were performed in 41 isoflurane-anesthetized dogs. In sinus rhythm dogs, peak AERP changes resulting from intravenous KB infusion ranged from (mean±SEM) 4.4±0.4% (1 mg/kg) to 14.8±2.6% (5 mg/kg; ED50=1.9 mg/kg). AERP was maximally prolonged between 5 and 10 minutes after beginning of KB infusion and returned to baseline values within 30 minutes thereafter. Rapid atrial pacing–induced AF reversibly shortened AERP (P<0.001) in 5 dogs, averaging 14.9±2.1% after 90 minutes of AF. Both the time course and magnitude of mean AERP changes in 5 AF dogs receiving 5 mg/kg KB were indistinguishable from those in 5 sinus rhythm dogs receiving an equivalent KB dose (P>0.05). We measured cardiac tissue and arterial plasma KB concentrations produced by intravenous infusion (1 mg · kg-1 · min-1) of 5 mg/kg KB. Plasma drug concentration peaked at the end of KB infusions (30.86±3.26 nmol/L; n=4 dogs) and declined to 0.56±0.19 nmol/L after 100 minutes. The cardiac tissue-to-plasma drug concentration gradient averaged {approx}40 at 100 minutes after start of KB infusion. KB at concentrations achieved in vivo irreversibly blocked NCX-mediated Ca2+ influx in isolated canine right atrial myocytes by {approx}60%, but had no significant effect on NCX-dependent Ca2+ extrusion.

Conclusion— NCX-mediated Ca2+ influx plays an important role in acute, AF-induced AERP shortening.


Key Words: atrium • fibrillation • electrophysiology




This article has been cited by other articles:


Home page
EuropaceHome page
I. Savelieva and J. Camm
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches
Europace, June 1, 2008; 10(6): 647 - 665.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. P. Regan, L. Kiss, G. L. Stump, C. J. McIntyre, D. C. Beshore, N. J. Liverton, C. J. Dinsmore, and J. J. Lynch Jr.
Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 322 - 330.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
W. Wongcharoen, Y.-C. Chen, Y.-J. Chen, C.-M. Chang, H.-I Yeh, C.-I Lin, and S.-A. Chen
Effects of a Na+/Ca2+ exchanger inhibitor on pulmonary vein electrical activity and ouabain-induced arrhythmogenicity
Cardiovasc Res, June 1, 2006; 70(3): 497 - 508.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
G. L. Stump, A. A. Wallace, C. P. Regan, and J. J. Lynch Jr.
In Vivo Antiarrhythmic and Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1362 - 1367.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. G. Akar, T. H. Everett, R. Ho, J. Craft, D. E. Haines, A. P. Somlyo, and A. V. Somlyo
Intracellular Chloride Accumulation and Subcellular Elemental Distribution During Atrial Fibrillation
Circulation, April 8, 2003; 107(13): 1810 - 1815.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Rubart and D. P. Zipes
NO Hope for Patients With Atrial Fibrillation
Circulation, November 26, 2002; 106(22): 2764 - 2766.
[Full Text] [PDF]